Diridavumab (CR6261) (INN[1]) is a monoclonal antibody designed for the treatment of influenza A.[2]
This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.